ARDS vs. SCPS, EVLO, GNCAQ, GNCA, STAB, AMPE, CMRA, EFTR, ONCSQ, and PXMD
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Aridis Pharmaceuticals vs.
Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Scopus BioPharma has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 12.42, suggesting that its stock price is 1,142% more volatile than the S&P 500.
In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
Scopus BioPharma has higher earnings, but lower revenue than Aridis Pharmaceuticals.
9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Aridis Pharmaceuticals received 120 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Summary
Aridis Pharmaceuticals beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ARDS) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ARDS Stock Free ARDS Stock Alerts